NICE backs Gilead's hepatitis C drug Epclusa

23 September 2016

The National Institute for Health and Care Excellence (NICE), the cost-effectiveness watchdog for England and Wales, has recommended Epclusa (sofosbuvir-velpatasvir), from US biotech major Gilead Sciences (Nasdaq: GILD), as a treatment option for all genotypes of hepatitis C in draft guidance published today.

Sofosbuvir-velpatasvir is one of the newer direct acting anti-viral treatments for hepatitis C and works by blocking the virus from multiplying and infecting new cells. As trials for the drug showed high cure rates of 89% and above, the NICE appraisal committee concluded that sofosbuvir-velpatasvir was clinically and cost-effective, and should be routinely available on the National Health Service.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK